Aperio Group LLC Acquires New Holdings in Horizon Pharma PLC (HZNP)

Share on StockTwits

Aperio Group LLC acquired a new stake in Horizon Pharma PLC (NASDAQ:HZNP) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 16,415 shares of the biopharmaceutical company’s stock, valued at approximately $272,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in HZNP. Point72 Asset Management L.P. lifted its holdings in Horizon Pharma by 252.2% in the first quarter. Point72 Asset Management L.P. now owns 1,312,900 shares of the biopharmaceutical company’s stock valued at $18,643,000 after buying an additional 940,100 shares during the period. Millennium Management LLC lifted its holdings in Horizon Pharma by 299.2% in the first quarter. Millennium Management LLC now owns 1,124,465 shares of the biopharmaceutical company’s stock valued at $15,967,000 after buying an additional 842,814 shares during the period. venBio Select Advisor LLC lifted its holdings in Horizon Pharma by 16.3% in the first quarter. venBio Select Advisor LLC now owns 5,158,683 shares of the biopharmaceutical company’s stock valued at $73,253,000 after buying an additional 722,500 shares during the period. American Century Companies Inc. lifted its holdings in Horizon Pharma by 158.5% in the first quarter. American Century Companies Inc. now owns 706,775 shares of the biopharmaceutical company’s stock valued at $10,036,000 after buying an additional 433,359 shares during the period. Finally, Redwood Investments LLC lifted its holdings in Horizon Pharma by 43.9% in the first quarter. Redwood Investments LLC now owns 1,320,081 shares of the biopharmaceutical company’s stock valued at $18,745,000 after buying an additional 402,610 shares during the period. Institutional investors and hedge funds own 87.26% of the company’s stock.

Shares of NASDAQ:HZNP opened at $20.95 on Thursday. Horizon Pharma PLC has a 52 week low of $11.17 and a 52 week high of $21.25. The company has a quick ratio of 1.63, a current ratio of 1.70 and a debt-to-equity ratio of 2.19. The company has a market capitalization of $3.52 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 1.34 and a beta of 1.49.

Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.17. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. The firm had revenue of $302.84 million during the quarter, compared to the consensus estimate of $275.51 million. During the same quarter in the prior year, the firm earned $0.41 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. research analysts anticipate that Horizon Pharma PLC will post 1.34 EPS for the current year.

In other news, EVP Geoffrey M. Curtis sold 9,904 shares of the stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $20.63, for a total transaction of $204,319.52. Following the completion of the sale, the executive vice president now owns 28,767 shares of the company’s stock, valued at $593,463.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brian K. Beeler sold 15,433 shares of the stock in a transaction on Friday, June 8th. The stock was sold at an average price of $17.58, for a total transaction of $271,312.14. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.

Several brokerages recently weighed in on HZNP. BidaskClub lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a report on Thursday, June 28th. Citigroup downgraded shares of Horizon Pharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 27th. Zacks Investment Research raised shares of Horizon Pharma from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Tuesday, July 10th. Jefferies Financial Group upped their target price on shares of Horizon Pharma from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Stifel Nicolaus upped their target price on shares of Horizon Pharma from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 18th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Horizon Pharma currently has a consensus rating of “Buy” and an average price target of $21.00.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Further Reading: Do Tariffs Work?

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply